Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal sarcomatosis—A systematic review and meta-analysis

Abstract

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) play an important role in the treatment of various peritoneal surface malignancies, but its efficacy in peritoneal sarcomatosis (PS) remains unknown. Hence, we performed a systematic review and meta-analysis to investigate outcomes of CRS-HIPEC in PS, in accordance with PRISMA guidelines. 16 studies with a total of 320 patients were included in the meta-analysis. Pooled mean length of hospital stay after CRS-HIPEC was 16.0 days (95% CI: 12.2–19.8) and rate of serious complications was 17.4% (95% CI: 9.8–26.3). The median DFS was 12.0 months (95% CI: 8.0–16.0) and the 5-year DFS was 21.8% (95% CI: 13.2–31.7). Overall pooled median OS was 29.3 months (95% CI: 23.8–34.8), with a 5-year OS of 35.3% (95% CI: 26.3–44.8). Subgroup analysis showed that patients with CC-0 cytoreduction had a higher median OS of 34.6 months (95% CI: 23.2–45.9). Median OS for patients with a primary tumour histology of leiomyosarcoma and liposarcoma was 33.5 months (95% CI: 15.9–51.1) and 39.1 months (95% CI: 20.8–57.5) respectively. The site of recurrence was locoregional in 57.3% (95% CI: 38.9–74.8), distant in 17.3% (95% CI: 3.9–35.6), and both in 17.4% (95% CI: 5.8–32.2). In conclusion, our results suggest that CRS-HIPEC may improve outcomes in a select group of PS patients.